{sub}
}The same biological process that protects us from infection and injury becomes the quiet driver of the conditions that cause most death and disability — once it stops switching off. We can treat it. We barely measure it.
Acute resolves. Chronic never switches off.
Acute inflammation is one of the body's most useful responses — fast, local, and self-limiting.
When tissue is injured or infected, the immune system floods the site with signaling proteins and immune cells to clear the threat and begin repair. Built into that same response is an active program that shuts it down once the work is done.
Trouble begins when the off-switch fails. Inflammation settles into a low-grade, body-wide hum that can persist for years — driven by aging, chronic stress, poor diet, inactivity, and environmental exposure, and damaging tissue the entire time it runs.
That difference is the whole reason measurement is hard. Acute inflammation announces itself. Chronic inflammation is subtle by design — which is precisely why a once-a-year snapshot tends to miss it.
Same signaling machinery, opposite stories. The danger of chronic inflammation is that it stays just above baseline for years without ever producing the dramatic spike a single test is built to catch.
3/5
Three of every five deaths worldwide trace to inflammation-driven conditions.
Cardiovascular disease, cancer, diabetes, kidney and liver disease, autoimmune conditions, and neurodegeneration look like separate problems and sit in separate clinics. A growing body of research places the same driver upstream of all of them — carrying information about risk long before damage shows up on a scan.
Hover any disease to trace its link to chronic inflammation.
Two facts sit uncomfortably next to each other.
First, we already have therapies that work. Anti-inflammatory and immune-modulating drugs can genuinely change the course of many of these diseases.
Second, we have almost no way to watch inflammation as it behaves. CRP and its kin move on a timescale of hours to days, yet they are checked only a few times a year. We manage a fast, dynamic process with slow, infrequent snapshots — and disease gets caught reactively, after the damage is done.
The gap is not a shortage of drugs. It is the absence of a way to track immune dynamics in everyday life.
Inflammation climbs for weeks before symptoms surface. Test often enough and that hidden rise becomes a window to act — the blind spot, removed.
A single cytokine value, read on its own, is close to meaningless. It depends on your baseline, your age, your stress, the time of day. The meaning is in the movement.
{lead}
Inflammation was not a passenger — it was part of the engine. The catch: this smoldering vascular inflammation stays invisible to standard labs until something breaks.
The lesson repeats across all three: inflammation is the thing that matters, and we measure it too rarely, and too bluntly, to keep up with it.
Continuous glucose monitoring transformed diabetes care. Glucose was not a new biomarker — what changed was how often it was measured. Read continuously against a person's own baseline, a single number became a trajectory people could act on.
The same opportunity is open for inflammation. Measured often enough to reveal the slope, the same handful of markers stop being a post-mortem and start being an early-warning system. Is a treatment working? Is a flare building? Those are questions about direction — and direction only appears when you measure more than once.
The biomarker is the same. The difference is how often you look. Four points a year describe a snapshot; frequent readings describe a direction.
Inflammation is measurable, treatable, and sits upstream of the diseases that define modern chronic illness. The missing piece was never the biology — it was the ability to read the immune system often enough, and personally enough, to act before the damage is done.
{a[2]}